Liposomal delivery of dexamethasone attenuates prostate cancer bone metastatic tumor growth in vivo.

ABSTRACT:

Background

The inflammatory tumor microenvironment, and more specifically the tumor-associated macrophages, plays an essential role in the development and progression of prostate cancer towards metastatic bone disease. Tumors are often characterized by a leaky vasculature, which - combined with the prolonged circulation kinetics of liposomes - leads to efficient tumor localization of these drug carriers, via the so-called enhanced permeability and retention (EPR) -effect. In this study, we evaluated the utility of targeted, liposomal drug delivery of the glucocorticoid dexamethasone in a model of prostate cancer bone metastases.

Methods

Tumor-bearing Balb-c nu/nu mice were treated intravenously with 0.2-1.0-5.0 mg/kg/week free- and liposomal DEX for 3-4 weeks and tumor growt

SUBMITTER: Kroon J 

PROVIDER: S-EPMC5006873 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature